The prospects of CAR T-cell therapies in changing the therapeutic algorithm of neurologic autoimmunities
Therapeutic Advances in Neurological Disorders
Published online on March 17, 2026
Abstract
Therapeutic Advances in Neurological Disorders, Volume 19, January-December 2026.
T cells, genetically modified to express chimeric antigen receptors (CAR T), successfully used in hemato-oncologic malignancies, are showing promising and sustained benefits in refractory autoimmune neurological diseases, including Myasthenia Gravis, ...
T cells, genetically modified to express chimeric antigen receptors (CAR T), successfully used in hemato-oncologic malignancies, are showing promising and sustained benefits in refractory autoimmune neurological diseases, including Myasthenia Gravis, ...